Aurobindo Pharma's CuraTeQ Biologics Receives Health Canada NOC for Bevqolva
Published on: May 2, 2026, 11:38 p.m. | Source: scanx.trade
Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics has received Notice of Compliance from Health Canada for its bevacizumab biosimilar Bevqolva™, announced on May 1, 2026. The product, available in 100 mg and 400 mg formulations, treats multiple cancers including colorectal and lung by inhibiting angiogenesis. CuraTeQ previously launched Bevqolva™ commercially in the UK in 2025 and has the product under EMA review for European market access.
